Alpha-synuclein levels in multiple sclerosis patients with restless leg syndrome

Abstract

The restless legs syndrome is more frequent and critical in Multiple Sclerosis patients, and it harms their general well-being and life quality. Alpha-synuclein is a synuclein protein that can have an impact on the pathway of signaling, affecting the Dopamin 2 receptor and its receptor trafficking. Studies have shown that the decrease in dopamine 2 receptor and Restless Legs Syndrome disease are correlated. This study is aimed to ascertain the alpha-synuclein level in multiple sclerosis patients with restless legs syndrome. Materials and Methods: We took blood samples from 40 multiple sclerosis patients and 20 healthy individuals. Half of the patient group had Multiple Sclerosis with restless leg syndrome. In the study groups, the alpha-synuclein level was determined by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-dependent immunosorbent assay (ELISA). Results: Alpha-synuclein gene expression level was found or be significantly lower in restless leg syndrome patients with multiple sclerosis than the Alpha-synuclein gene expression level in the control group. Conclusion: Alpha-synuclein may have an impact on the pathogenesis of the restless leg syndrome of multiple sclerosis disease. Further investigations are required to determine the impact of alpha-synuclein in the pathogenesis of restless leg syndrome in multiple sclerosis disease.